Irpagratinib
Selleck Chemicals
SKU:E1979-1MG
Couldn't load pickup availability

Irpagratinib is an inhibitor of FGFR4 used in studies of MAPK / ERK Signaling. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling in cancer and cell signaling models.
By inhibiting FGFR4, Irpagratinib can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving FGFR4
- Pathway perturbation studies connected to MAPK / ERK Signaling
- Concentration-response inhibition and target-dependence studies
- Biochemical kinase assays, phospho-signaling studies, and selectivity profiling
Overall, Irpagratinib is appropriate when a defined chemical perturbant is needed to connect FGFR4 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- FGFR4
- Target Class:
- Kinase
- Pathways:
- MAPK / ERK Signaling
- Research Area:
- Cancer • Cell Signaling
- CAS No.:
- 2230974-62-4
- Molecular Weight:
- 570.59
- Formula:
- C₂₈H₃₂F₂N₆O₅
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.